Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
23. (KR1020090116831) NEW USE FOR CANNABINOID

Application Number: 1020097021239 Application Date: 15.11.2005
Publication Number: 1020090116831 Publication Date: 11.11.2009
Publication Kind : A
IPC:
A61K 31/33
A61K 36/55
A61P 3/04
A61P 25/28
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18
Magnoliophyta (angiosperms)
185
Magnoliopsida (dicotyledons)
55
Linaceae (Flax family), e.g. Linum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
04
Anorexiants; Antiobesity agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CPC:
A61K 31/352
A61K 36/00
A61K 36/185
Applicants: GW PHARMA LIMITED
지더블유 파마 리미티드
Inventors: GUY GEOFFREY
가이, 제프리
PERTWEE ROGER
페르트위, 로저
Agents: 이원희
Priority Data: 0425248.2 16.11.2004 GB
0515704.5 29.07.2005 GB
Title: (EN) NEW USE FOR CANNABINOID
(KO) 카나비노이드의 새로운 용도
Abstract:
(EN) The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency. COPYRIGHT KIPO&WIPO 2010
(KO) 본 발명은 카나비노이드 수용체인 CB의 중립성 길항작용에 의해 이득을 얻는 질병 및 병리현상의 치료를 위한 약제 제조에 이용되는 카나비노이드(cannabinoid)의 하나 또는 그 이상의 용도에 관한 것이다. 상기 카나비노이드는 바람직하게는 테트라하이드로카나비노이드(THCV: tetrahydrocannabivarin)이다. 상기 CB의 중립성 길항작용에 의해 이득을 얻는 질병 및 병리현상은 다음의 군으로부터 선택되어 치료될 수 있다: 비만증, 정신분열증, 간질, 알츠하이머같은 인지장애, 골격장애, 폭식증, 제2형 당뇨병(인슐린 비-의존성 당뇨병)과 관련된 비만증 및 약물, 알코올 및 니코틴 남용 또는 의존증. 1 1